莫西沙星在儿童耐药结核中的药代动力学、心脏安全性与剂量研究
结果显示莫西沙星表观清除率受矮小和HIV感染影响, crushed或混悬片剂吸收更快,QTcF最大变化中位数16.3 ms,无患儿QTcF≥500 ms;模型模拟提示现有儿童剂量偏低,可能需要高于10-15 mg/kg的剂量才能达到成人暴露水平,但需进一步安全性评估。
要点
- 儿童RR-TB患者中莫西沙星表观清除率受矮小和HIV感染影响而增加。
- 莫西沙星QTcF最大变化中位数16.3 ms,无患儿QTcF≥500 ms。
- 模型模拟提示现有儿童剂量偏低,可能需要高于10-15 mg/kg。
核心结论
- 儿童RR-TB患者可能需要高于10-15 mg/kg的莫西沙星剂量才能达到成人暴露水平,但需进一步安全性评估,尤其与其它延长QT药物合用时。
研究设计与样本
- 采用NONMEM进行群体药代动力学和Fridericia校正QT间期(QTcF)延长分析,并进行药代动力学模拟预测暴露和最优权重分段剂量。
主要发现
- 药代动力学采样日莫西沙星中位剂量为11 mg/kg(范围6.1-17 mg/kg)。
- 典型16 kg儿童的表观清除率为6.95 L/h,矮小和HIV感染增加表观清除率, crushed或混悬片剂吸收更快。
- 莫西沙星给药后QTcF最大变化中位数为16.3 ms(范围-27.7至61.3 ms),无患儿QTcF≥500 ms。
- 浓度-QTcF关系呈非线性,最大药物效应(Emax)为8.80 ms(个体间变异=9.75 ms),氯法齐明使用使Emax增加3.3倍。
临床怎么用
- 临床使用莫西沙星治疗儿童RR-TB时,应关注当前推荐剂量可能偏低,尤其年幼儿童可能需要高于10-15 mg/kg的剂量。
- 合并HIV感染或矮小的患儿因表观清除率增加,可能需要调整剂量。
- 与氯法齐明等延长QT药物合用时需加强QT间期监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Moxifloxacin is a recommended drug for rifampin-resistant tuberculosis (RR-TB) treatment, but there is limited pediatric pharmacokinetic and safety data, especially in young children. We characterize moxifloxacin population pharmacokinetics and QT interval prolongation and evaluate optimal dosing in children with RR-TB. METHODS: Pharmacokinetic data were pooled from 2 observational studies in South African children with RR-TB routinely treated with oral moxifloxacin once daily. The population pharmacokinetics and Fridericia-corrected QT (QTcF)-interval prolongation were characterized in NONMEM. Pharmacokinetic simulations were performed to predict expected exposure and optimal weight-banded dosing. RESULTS: Eighty-five children contributed pharmacokinetic data (median [range] age of 4.6 [0.8-15] years); 16 (19%) were aged <2 years, and 8 (9%) were living with human immunodeficiency virus (HIV). The median (range) moxifloxacin dose on pharmacokinetic sampling days was 11 mg/kg (6.1 to 17). Apparent clearance was 6.95 L/h for a typical 16-kg child. Stunting and HIV increased apparent clearance. Crushed or suspended tablets had faster absorption. The median (range) maximum change in QTcF after moxifloxacin administration was 16.3 (-27.7 to 61.3) ms. No child had QTcF ≥500 ms. The concentration-QTcF relationship was nonlinear, with a maximum drug effect (Emax) of 8.80 ms (interindividual variability = 9.75 ms). Clofazimine use increased Emax by 3.3-fold. Model-based simulations of moxifloxacin pharmacokinetics predicted that current dosing recommendations are too low in children. CONCLUSIONS: Moxifloxacin doses above 10-15 mg/kg are likely required in young children to match adult exposures but require further safety assessment, especially when coadministered with other QT-prolonging agents.
引用
- Radtke KK, Hesseling AC, Winckler JL, et al. Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children. Clin Infect Dis. 2022. PMID: 34286843. doi:10.1093/cid/ciab641
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。